Articles tagged with Melanoma Cells
A study by UMMS researchers has identified a protein called GDF6 as a primary role in metastatic melanoma, found to be expressed in 80% of human melanomas and correlated with increased melanoma growth and spread. The findings offer new therapeutic potential for treatment-resistant skin cancer.
Researchers identified AMIGO2 and PTK7 as key players in melanoma cell growth and survival. Targeting these proteins may lead to new treatments for metastatic melanoma.
Melanocyte stem cells can become cancerous when accumulating sufficient genetic mutations, which are activated by UV radiation from the sun. Researchers at Cornell University discovered a key gene, Hgma2, that facilitates melanoma development.
Researchers have identified melanocytes as the origin of cutaneous melanoma, a deadly form of skin cancer. These cells are reprogrammed to become invasive and migratory cancer cells, leading to tumor formation.
A study led by NYU Langone Health found that removing a 2mm margin from suspicious moles can completely remove cancer cells with a single procedure. Researchers monitored patients for over a year and found no further suspicious growths, with 90% of biopsied moles being completely removed.
Researchers at UNC Lineberger Comprehensive Cancer Center have discovered a way to protect T-cells that are normally blocked from attacking melanoma cells, allowing them to go on to attack cancer. By combining this strategy with an existing immunotherapy treatment, they found that it can shrink melanoma tumors and prolong survival in p...
Researchers at Penn and Wistar Institute found that melanoma cells bypass BRAF inhibitor blockades by activating parallel pathways governed by PAK enzymes, leading to increased aggressiveness.
A study at The Wistar Institute has discovered a slowly proliferating and highly invasive melanoma cell subpopulation that can leave the primary tumor and colonize distant sites. These cells express higher levels of the protein SerpinE2, which plays a critical role in melanoma invasion.
This study identifies the role of tumor-infiltrating B cells in promoting melanoma progression and resistance to therapy. The researchers found that depletion of B cells in the tumor microenvironment shows antitumor activity in patients with advanced metastatic melanoma.
A study found that vessel growth created by tumors can enhance immunotherapy effects against melanoma. The growth secreted chemokines that attracted T cells into the tumor environment, leading to long-lasting anti-tumor immunity.
A new international research project has identified four distinct subtypes of uveal melanoma, a rare and deadly eye cancer. The study suggests that each subtype requires different management strategies due to unique genomic abnormalities and patient outcomes.
New research reveals a two-step process for cell immortalization and cancer development, with telomerase playing a complex role. Telomerase levels are insufficient to lengthen all telomeres, leading to genomic instability and tumor formation.
Researchers found that anti-CTLA-4 and anti-PD-1 checkpoint inhibitors expand distinct immune infiltrates against cancer by targeting different types of T cells. This study provides a reason why combining these therapies works better than either alone.
Researchers have improved the properties of an AMP from a spider, making it more effective against bacteria and cancer cells. The modified peptide was found to be 10 times better at killing most bacteria than the previous cyclic form, while also selectively targeting certain types of cancer cells.
Researchers develop noninvasive method to gauge cell stiffness, a key indicator of diseases like cancer and asthma. By analyzing particles' movements at high frame rates, scientists can determine a cell's mechanical properties without direct contact.
Researchers at Penn State have developed a compound that inhibits tumor growth by 69% in a mouse model and killed human melanoma cells. The compound targets the Akt1 pathway and human topoisomerase IIα activity, contributing to melanoma tumor growth.
Tumor cells develop resistance to immunotherapy by downregulating MHC class I molecules and triggering immunosuppressive processes. Inhibiting the epigenetic control protein Ezh2 improves treatment efficacy, leading to increased tumor mass shrinkage and extended tumor-free survival.
A team of NYU researchers has pinpointed a sugar modification in cells that spurs the spread of skin cancer, specifically melanoma. The study reveals that silencing FUT8 enzyme suppresses cancer onset and tumor dissemination in laboratory mice.
Researchers have developed a chemical array technique that can identify and culture malignant stem-like cells within melanoma tumors. This allows for the creation of patient-specific models for individualized cancer treatment.
Researchers have developed a new microscopic technique to analyze single melanoma cells, which are often irregular and dark, making them difficult to investigate. The technique, using modified photoacoustic spectroscopy, can detect non-uniform cancer cells and track their spread.
Researchers have discovered that FES, a protein previously linked to cancer development, actually acts as a tumor suppressor in melanoma. The study found that restoring FES expression through epigenetic drugs may provide a novel therapeutic strategy against melanoma.
The Melanoma Research Alliance awarded Dr. Neville Sanjana a grant to use CRISPR technology to identify genetic mutations causing immunotherapy resistance in melanoma. The goal is to create a list of actionable mutations for patients enrolled in melanoma immunotherapy trials.
A team of researchers identified the CD103 molecule as crucial for the long-term residence and potent anti-tumor response of T cells in the skin. This finding supplements a previous discovery that T cells residing in the skin are responsible for a strong protective response against melanoma.
A new study by Dartmouth researchers reveals that resident memory T cells reside in the skin, where they can quickly eliminate melanoma cells. This finding suggests that these immune cells play a crucial role in protecting against future tumors and may serve as a target for future cancer therapies.
A team of researchers at the University of Iowa documented how melanoma cells form tumors in a 3D model, finding similarities with breast tissue cancer cells. They identified two drugs, anti-beta 1 integrin/(CD29) and anti-CD44, that block tumor creation in both types of cancer.
Researchers at UCI have identified a specific mutation that allows melanoma tumor cells to evade the immune system. This finding may lead to more effective immunotherapies and targeted treatments for patients with melanoma.
A recent NIH study identified 40 new genes affected by HIF1α in melanoma, offering potential new targets for treatment. The research also found connections between gene expression and the spread of cancer cells, which could help predict tumor progression.
A QUT-led project has identified the mechanism by which melanoma cells switch from proliferative to invasive behavior, opening up new pathways for cancer treatment. The discovery reveals a specific regulatory pathway involving the NFIB-EZH2 axis, which could potentially be targeted with existing drugs.
A Yale-led research team found that a melanoma cell and a white blood cell can fuse to form a hybrid with the ability to metastasize, providing insight into how cancer spreads from solid tumors.
A new study by Ludwig Institute for Cancer Research has identified an ancient cellular response that underlies the spread of melanoma. The findings show that punishing conditions within the tumor prompt a subset of tumor cells to become invasive, and suggest novel strategies for treating this form of skin cancer.
Researchers at Michigan State University have discovered a chemical compound that can stop the spread of melanoma cells by up to 90 percent. The compound targets a gene's ability to produce RNA molecules and proteins in melanoma tumors, effectively shutting down the disease's progression.
Epigenetic changes in melanoma cells have been identified as key drivers of cancer metastasis. The study, published in Oncotarget, found that these changes can be reversed, making them a potential target for new therapies.
Researchers at LSU Health New Orleans report a complete response in a patient with long history of melanoma after treatment with a combination of an interferon and melanoma vaccine. The FDA has approved a first-of-its-kind therapy, talimogene laherparepvec, which shows a 10.8% complete response rate.
A Penn study found that decreased levels of the gene p15 can distinguish nevi from melanomas. The protein p15 inhibits nevus cell proliferation and can be used as a biomarker to identify borderline cases.
Researchers at CNIO have discovered CPEB4, a protein essential for melanoma cell survival and proliferation. The protein regulates the expression of factors unique to this tumour type, making melanomas more vulnerable to drugs targeting this pathway.
Researchers found that culturing T cells in N-acetyl cysteine (NAC) before infusion improved effectiveness and outcomes in a preclinical model of melanoma. Nearly 40% of NAC-cultured T cells were detectable in tumors after transfer, compared to approximately 1.2% of standard-culture T cells.
An experimental cancer drug called pevonedistat has shown significant promise in stopping melanoma, possibly other cancers. The drug works by blocking a specific protein that allows malignant cells to replicate rapidly.
Researchers found that inhibiting RMEL3, a non-coding RNA, reduces melanoma cell proliferation by up to 95%. The study suggests RMEL3 is expressed in most cases of melanoma and offers promising therapeutic and diagnostic potential.
Researchers at UCI have discovered a new treatment method for metastatic melanoma by blocking the 'don't eat me' signaling protein CD47 on melanoma cells, increasing their phagocytosis by macrophages. This approach, combined with targeting another cell surface protein CD271, resulted in near complete elimination of metastasis from mice.
A new study pinpoints when melanoma cells metastasize to the brain months before they develop into fatal tumors. Researchers discovered that micro-tumor cells hijack astrogliosis to support metastatic growth, leading to potential early detection and intervention.
Colorado State University researcher Jesse Wilson is developing a new microscope that can distinguish between benign and malignant pigmented skin lesions without a biopsy. The pump-probe technology uses a simpler laser source that's already widely used in telecommunications applications, making it more realistic for melanoma applications.
Researchers developed a novel synthesis method for glaziovianin A from parsley and dill seeds, inhibiting human tumor cell growth. The compounds also showed promise in testing human cancer cells, with the parent compound being the most active anti-tubulin agent.
A large-scale study found a slight increase in risk of cutaneous melanoma among men taking PDE5 inhibitors for erectile dysfunction, but this was largely explained by greater sun exposure. The study suggests that these drugs are unlikely to be associated with an increased risk of skin cancer.
Researchers discovered that natural killer cells can remember and target pigmented skin cells, potentially treating malignant melanoma and vitiligo. The immune system uses the NLRP3 inflammasome as a checkpoint to trigger this response.
A recent study published at ASCO found that gene dysregulation causes immune T cells to turn back to an immature state, making them less effective against metastatic melanoma. The researchers discovered over 60 epigenetic changes and 10 changes in gene activity that were most common among patients who didn't respond to immunotherapy.
Researchers at Ruhr-University Bochum have discovered an olfactory receptor in melanocytes, which can be activated by Beta-Ionone to regulate enzyme activity and cell growth. This finding offers new potential for treating melanoma and other pigmentation disorders.
A Moffitt Cancer Center study found that combining nivolumab and ipilimumab is an active treatment option for small cell lung cancer patients who have failed initial therapy. The two-drug immunotherapy regimen resulted in responses that lasted longer than many other investigational agents, with 20% of patients showing a response.
Researchers successfully treated a patient with metastatic melanoma using a combined approach of immunotherapy, including IL-21-primed polyclonal CTL plus CTLA4 blockade. The treatment led to the complete disappearance of tumors and sustained disease-free status for five years.
Researchers identified a type of skin cell as the target of the virus in humans and found that an FDA-approved drug can block viral infection. The study establishes a new way to investigate this type of oncogenic viral infection and provides hope for better treatments.
Scientists at TSRI have discovered a mechanism that turns mutant cells into aggressive cancers. The research identifies the role of POT1 mutations and their impact on the cell's ability to repair DNA damage.
A study by Sanford Burnham Prebys Medical Discovery Institute identified a super-oncogenic protein, activating transcription factor 2 (ATF2), that drives the formation of melanoma in mice with BRAF mutations. Inactive ATF2 was found to cause tumors to develop slower than expected, making it a potential indicator of tumor aggressiveness.
Researchers found that a tumor suppressor gene helps repair UV damage in cells, reducing the risk of skin cancers like melanoma. The study suggests this gene may serve as a biomarker for skin cancer prevention and offers hope for new drug targets.
Researchers combine radiation treatments with new immunotherapies to target melanoma, showing synergistic effects that improve treatment outcomes. The combination of radiation and immunotherapy has been shown to increase one-year survival rates for patients with Stage 4 metastatic melanoma.
A study published in JAMA found that pembrolizumab, an antibody against PD-1, was associated with a 33% objective response rate and 23-month median overall survival in patients with advanced melanoma. The treatment also showed improved progression-free survival rates of 35% at 12 months and 52% at 12 months
The white paper outlines key takeaways, including the importance of proper sunscreen use to reduce melanoma risk by up to 50%, developing more precise diagnosis methods, and overcoming immunotherapy resistance. The research aims to advance treatment and potentially cure melanoma by understanding its unique characteristics.
Research shows that aged tumor cells in melanoma are more metastatic and resistant to treatment with targeted therapies due to changes in the microenvironment. Antioxidants, such as N-acetylcysteine, may be a better treatment strategy for older patients.
Researchers at VIB, KU Leuven and UGent have discovered a non-coding RNA gene called SAMMSON that is specifically expressed in human malignant melanoma. The growth of aggressive skin cancer is highly dependent on this gene, paving the way for improved diagnostic tools and treatment options.
A new microscope enables the visualization of cancer cells in 3D, revealing that these cells form small protrusions called blebs in a more realistic tumor environment. This discovery is a first step toward understanding 3D biology in tumor microenvironments and may help explain skin cancer cell invasiveness and drug resistance.
The study discovered that cancer begins after activation of an oncogene or loss of a tumor suppressor, involving a change that takes a single cell back to a stem cell state. Targeting specific genes could stop cancer from ever starting.
Researchers at The Wistar Institute used patient-derived xenograft (PDX) mouse models to test a combination of targeted therapies against relapsed melanoma. A MET inhibitor called capmatinib, when combined with BRAF and MEK inhibitors, showed significant tumor regression in all animals, suggesting a possible new mechanism of resistance.